Brief: Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
06/02/2024 14:36
Feb 6 (Reuters) - Lipocine Inc LPCN.O :
* LIPOCINE ANNOUNCES CONFIRMATION OF DOSING REGIMEN FOR
PIVOTAL
STUDY OF LPCN 1154
* LIPOCINE INC - ON TRACK FOR Q2-24 PIVOTAL STUDY TOPLINE
RESULTS
AND PLANNED Q4-24 NDA FILING
Source text for Eikon: ID:nPn8HZLj4a
Further company coverage: LPCN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy